Renalyx Health Systems has unveiled the RENALYX – RxT 21, the world’s first fully indigenous, AI and cloud-enabled smart hemodialysis machine, marking a groundbreaking leap in kidney care innovation. Priced from INR 6.70 lakh, the RxT 21 is significantly more affordable than imported alternatives, making dialysis accessible to underserved populations, especially in semi-urban and rural regions.
Completely designed and manufactured in India, the RxT 21 leverages advanced technologies such as real-time remote monitoring, AI-driven treatment optimization, and cloud-integrated nephrology platforms. These features enable clinicians to monitor patient conditions remotely and adjust treatments dynamically, ensuring better outcomes while keeping operational costs low. The machine addresses the needs of patients with end-stage renal disease (ESRD), cardiovascular complications, pulmonary disorders, and acute kidney injuries.
Renalyx becomes the first Indian company—and only the sixth globally—to develop a dialysis machine that has achieved EU CE certification, a testament to its adherence to international safety and quality standards. This milestone solidifies Renalyx’s position as a serious contender in the global renal care market.
To meet growing demand, the company plans to scale production to 5,000 units by FY25-26, followed by 1,500 additional machines by FY27-28. The initial rollout will target Maharashtra and Karnataka, with future expansion across India and to international markets. Renalyx has already secured orders from South Africa, the United States, and Europe. The company also plans to deploy RxT 21 machines in primary health centers, community clinics, and private dialysis facilities nationwide.
Renalyx has partnered with Bharat Electronics Ltd. (BEL) to manufacture 6,000 units of its earlier RxT 17 model—offering standard features—for deployment in resource-limited settings. Together, the RxT 21 and RxT 17 aim to significantly improve the affordability and accessibility of dialysis in India.
The company intends to invest INR 800 crores over the next four years to expand its manufacturing capabilities in Bengaluru, Mysuru, and Mumbai. Funding will be sourced through equity sales, debt financing, and promoter investments, with plans for an IPO within the next three years.
Founded in 2012 and headquartered in Bengaluru, Renalyx Health Systems is ISO 13485 certified and dedicated to transforming kidney care through connected medical technologies. With innovations like the RxT 21, Renalyx is redefining renal care both in India and globally.